Motus GI Holdings – MOTS (medical technology company) - 500 Beiträge pro Seite
eröffnet am 23.07.20 22:21:36 von
neuester Beitrag 19.02.21 21:11:31 von
neuester Beitrag 19.02.21 21:11:31 von
Beiträge: 15
ID: 1.328.271
ID: 1.328.271
Aufrufe heute: 0
Gesamt: 543
Gesamt: 543
Aktive User: 0
ISIN: US62014P5044 · WKN: A3EUTL · Symbol: MOTS
0,1056
USD
+14,16 %
+0,0131 USD
Letzter Kurs 18.05.24 Nasdaq OTC
Werte aus der Branche Gesundheitswesen
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 7,0000 | +6.045,74 | |
| 0,8600 | +36,51 | |
| 0,8600 | +17,95 | |
| 1,2900 | +12,17 | |
| 2,0600 | +11,35 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 1,9080 | -14,82 | |
| 3,0100 | -17,31 | |
| 0,6000 | -18,92 | |
| 1,4500 | -21,62 | |
| 3,5800 | -24,79 |
Feedback
Habe heute hier eine erste Position aufgebaut. Auf Sicht der nächsten 6-9 Monate denke ich ein interessantes Chance/Risiko Verhältnis. Gute nutzenbringende Technology nach meiner Ansicht. First mover advantage – Keine Wettbewerber. In Anbetracht von Covid-19 hat die Technologie insbesondere den Vorteil, die Verweiltagedauer im Krankenhaus zu verkürzen.
Presentation May 2020
https://ir.motusgi.com/
Motus GI Holdings, Inc. is a medical technology company, with subsidiaries in the U.S. and Israel, providing endoscopy solutions that improve clinical outcomes and enhance the cost-efficiency associated with the diagnosis and management of gastrointestinal conditions.
Market Cap: ~ $34 million
Cash: $21.5 million (vermutlich ~ $14.5 million Ende Q2)
50% Kostensenkungsmaßnahmen umgesetzt. Die vierteljährliche burn rate beträgt nun ~ $3 million.
Presentation May 2020
https://ir.motusgi.com/
Motus GI Holdings, Inc. is a medical technology company, with subsidiaries in the U.S. and Israel, providing endoscopy solutions that improve clinical outcomes and enhance the cost-efficiency associated with the diagnosis and management of gastrointestinal conditions.
Market Cap: ~ $34 million
Cash: $21.5 million (vermutlich ~ $14.5 million Ende Q2)
50% Kostensenkungsmaßnahmen umgesetzt. Die vierteljährliche burn rate beträgt nun ~ $3 million.
Sehr interessantes Interview mit dem CEO von Motus. Meiner Meinung nach zeigt es das große Potenzial des Unternehmens.
Einige Auszüge - 15:30 min
“Before Covid the number one value proposition we bring to the market is the ability to impact patient flow, avoiding delays or repeat procedures… In the era of Covid many of our Docs said the value proposition is now even more amplified.”
Interview mit dem CEO
15. Juni 2020
https://www.vifiresidechat.com/motusgi
Einige Auszüge - 15:30 min
“Before Covid the number one value proposition we bring to the market is the ability to impact patient flow, avoiding delays or repeat procedures… In the era of Covid many of our Docs said the value proposition is now even more amplified.”
Interview mit dem CEO
15. Juni 2020
https://www.vifiresidechat.com/motusgi
Habe hier heute meine Position deutlich vergrößert. Nur eine Frage der Zeit wann es hier deutlich höhere Kurse gibt...
Dr. Jason Samarasena, a key interventional gastroenterologist at UCI, shared the following thoughts based on his experience to date, "Pure-Vu® has been instrumental in addressing the clinical needs of our colonoscopy patients that present in the GI Lab with inadequate bowel prep. Inadequately prepped patients are a problem that we see regularly, and before the Pure-Vu® System’s availability, these patient's procedures were either delayed or even aborted prior to completion, leading to unnecessary additional nights of hospitalization. Pure-Vu® has allowed us to diagnose these patients earlier, which enables us to therapeutically treat when appropriate. Especially in light of Covid-19, we strive to avoid extended hospitalizations due to insufficient bowel prep and with Pure-Vu® we believe we can get a high-quality exam in less than 24 hours on most patients. This has a significant impact not only on overall patient care but also hospital economics."
Second Quarter 2020 Financial Results and Provides Corporate Update
August 11, 2020
https://ir.motusgi.com/press-releases/detail/75/motus-gi-rep…
Dr. Jason Samarasena, a key interventional gastroenterologist at UCI, shared the following thoughts based on his experience to date, "Pure-Vu® has been instrumental in addressing the clinical needs of our colonoscopy patients that present in the GI Lab with inadequate bowel prep. Inadequately prepped patients are a problem that we see regularly, and before the Pure-Vu® System’s availability, these patient's procedures were either delayed or even aborted prior to completion, leading to unnecessary additional nights of hospitalization. Pure-Vu® has allowed us to diagnose these patients earlier, which enables us to therapeutically treat when appropriate. Especially in light of Covid-19, we strive to avoid extended hospitalizations due to insufficient bowel prep and with Pure-Vu® we believe we can get a high-quality exam in less than 24 hours on most patients. This has a significant impact not only on overall patient care but also hospital economics."
Second Quarter 2020 Financial Results and Provides Corporate Update
August 11, 2020
https://ir.motusgi.com/press-releases/detail/75/motus-gi-rep…
Motus GI soll an der 32. jährlichen Gesundheitskonferenz von Piper Sandler teilnehmen.
http://www.globenewswire.com/news-release/2020/11/25/2133699…
http://www.globenewswire.com/news-release/2020/11/25/2133699…
Motus GI and Memorial Hermann Hospital Partner to Improve its Colonoscopy Efficiencies
December 02, 2020
FORT LAUDERDALE, Fla., Dec. 02, 2020 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc., (NASDAQ: MOTS) ("Motus GI" or the "Company"), a medical technology company providing endoscopy solutions that improve clinical outcomes and enhance the cost-efficiency associated with the diagnosis and management of gastrointestinal conditions, announced today a collaboration with Dr. Nirav Thosani, Director of Advanced Endoscopy, Memorial Hermann Hospital in Houston, Texas, to incorporate the Company’s Pure-Vu® System with the aim of improving efficiencies and clinical outcomes of inpatient colonoscopy procedures at Memorial Hermann Hospital, for patients who present with inadequate bowel preparation. The Memorial Hermann Hospital is a flagship hospital within the Memorial Hermann System, which is one of the largest not-for-profit health systems in Texas, owning and operating 14 hospitals.
https://ir.motusgi.com/press-releases/detail/84/motus-gi-and…
December 02, 2020
FORT LAUDERDALE, Fla., Dec. 02, 2020 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc., (NASDAQ: MOTS) ("Motus GI" or the "Company"), a medical technology company providing endoscopy solutions that improve clinical outcomes and enhance the cost-efficiency associated with the diagnosis and management of gastrointestinal conditions, announced today a collaboration with Dr. Nirav Thosani, Director of Advanced Endoscopy, Memorial Hermann Hospital in Houston, Texas, to incorporate the Company’s Pure-Vu® System with the aim of improving efficiencies and clinical outcomes of inpatient colonoscopy procedures at Memorial Hermann Hospital, for patients who present with inadequate bowel preparation. The Memorial Hermann Hospital is a flagship hospital within the Memorial Hermann System, which is one of the largest not-for-profit health systems in Texas, owning and operating 14 hospitals.
https://ir.motusgi.com/press-releases/detail/84/motus-gi-and…
Trading Spotlight
👍
Motus GI Announces Clinical Compendium of Pure-Vu System Patient Case Studies As Reported by Several Leading U.S. Hospitals
December 16, 2020
FORT LAUDERDALE, Fla., Dec. 16, 2020 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc., (NASDAQ: MOTS) ("Motus GI" or the "Company"), a medical technology company providing endoscopy solutions that improve clinical outcomes and enhance the cost-efficiency associated with the diagnosis and management of gastrointestinal conditions, announced today that it has collected a series of case studies from several leading U.S. hospitals which highlight the advantages of utilizing its Pure-Vu System to successfully complete emergent or challenging colonoscopies for patients with inadequately prepared colons. The case studies are now available on the Motus GI website.
Tim Moran, chief executive officer of Motus GI, stated, "As we’ve expanded the number of commercial placements for the Pure-Vu System into the flagship hospital of many of the leading health systems across the U.S., the feedback has been overwhelmingly positive. The patient case studies we’ve released today highlight the real-world impact our system has on optimizing care for patients who need an immediate colonoscopy or suffer from a comorbidity that precludes them from completing their prep regimen.”
https://ir.motusgi.com/press-releases/detail/85/motus-gi-ann…
Motus GI Announces Clinical Compendium of Pure-Vu System Patient Case Studies As Reported by Several Leading U.S. Hospitals
December 16, 2020
FORT LAUDERDALE, Fla., Dec. 16, 2020 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc., (NASDAQ: MOTS) ("Motus GI" or the "Company"), a medical technology company providing endoscopy solutions that improve clinical outcomes and enhance the cost-efficiency associated with the diagnosis and management of gastrointestinal conditions, announced today that it has collected a series of case studies from several leading U.S. hospitals which highlight the advantages of utilizing its Pure-Vu System to successfully complete emergent or challenging colonoscopies for patients with inadequately prepared colons. The case studies are now available on the Motus GI website.
Tim Moran, chief executive officer of Motus GI, stated, "As we’ve expanded the number of commercial placements for the Pure-Vu System into the flagship hospital of many of the leading health systems across the U.S., the feedback has been overwhelmingly positive. The patient case studies we’ve released today highlight the real-world impact our system has on optimizing care for patients who need an immediate colonoscopy or suffer from a comorbidity that precludes them from completing their prep regimen.”
https://ir.motusgi.com/press-releases/detail/85/motus-gi-ann…
Analysts Set Motus GI Holdings Price Target at $2.40
Motus GI Holdings, Inc. (NASDAQ:MOTS) has received a consensus recommendation of “Buy” from the six brokerages that are presently covering the firm , Marketbeat.com reports. One analyst has rated the stock with a sell recommendation and five have given a buy recommendation to the company. The average 1-year target price among brokerages that have updated their coverage on the stock in the last year is $2.40.[...]
https://zolmax.com/investing/analysts-set-motus-gi-holdings-…
Motus GI Expands Intellectual Property Portfolio with U.S. Patent for the Pure-Vu® System’s Universal Method to Mount on the End of Most Commercial Colonoscopes
January 11, 2021
Receives additional EU Patent for the Pure-Vu® System that protects the design of its fecal waste evacuation channels
https://ir.motusgi.com/press-releases/detail/86/motus-gi-exp…
January 11, 2021
Receives additional EU Patent for the Pure-Vu® System that protects the design of its fecal waste evacuation channels
https://ir.motusgi.com/press-releases/detail/86/motus-gi-exp…
Motus GI Announces European Clearance of Enhanced Pure-Vu® GEN2 System to Harmonize with U.S. Configuration
January 15, 2021
Regulatory approval for enhanced system is a key milestone that supports evaluation of strategic partnership opportunities in the EU
- - -
U.S. commercial rollout of Pure-Vu® GEN2 System enhancements initiated in Q4 2020
https://www.motusgi.com/news-media/press-releases/detail/87/…
January 15, 2021
Regulatory approval for enhanced system is a key milestone that supports evaluation of strategic partnership opportunities in the EU
- - -
U.S. commercial rollout of Pure-Vu® GEN2 System enhancements initiated in Q4 2020
https://www.motusgi.com/news-media/press-releases/detail/87/…
Ziemlich hohes Handelsvolumen die letzten Tage mit schöner Aufwärtsbewegung 
Ggf. knacken wir morgen die $2 Marke…
Ggf. knacken wir morgen die $2 Marke…
Antwort auf Beitrag Nr.: 66.459.419 von iknowtheway am 15.01.21 15:53:28Hi iknowtheway
Starker Anstieg unter hohem Volumen. Aber einfach so? Konnte keine News finden.
Hast Du was gefunden?
Bester Gruß
Straumen
Starker Anstieg unter hohem Volumen. Aber einfach so? Konnte keine News finden.
Hast Du was gefunden?
Bester Gruß
Straumen
Antwort auf Beitrag Nr.: 66.517.097 von straumen am 20.01.21 09:13:21Hallo straumen, konnte keine News finden. Vielleicht noch Nachwehen zur News vom 15. Januar. Die Aktie war wohl etwas unterbewertet im Vergleich zum (nach meiner Meinung etwas überhitzten) Gesamtmarkt.
Antwort auf Beitrag Nr.: 66.517.097 von straumen am 20.01.21 09:13:21Überhitzter Markt - ja sehe ich auch so, allerdings so lange die Welle läuft, einfach mit reiten.
Immer den Finger am Abzug, um nicht der Letzte zu sein, der das Licht aus macht
Immer den Finger am Abzug, um nicht der Letzte zu sein, der das Licht aus macht
Motus on the move - jetzt über $2 👍
Warum dieser Absturz heute?
DurchsuchenBeitrag zu dieser Diskussion schreiben
Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie eine neue Diskussion.
Investoren beobachten auch:
| Wertpapier | Perf. % |
|---|---|
| +18,18 | |
| 0,00 | |
| -0,48 | |
| -1,72 | |
| -1,59 | |
| +2,06 | |
| -3,08 | |
| -1,42 | |
| -7,62 | |
| -2,94 |
Meistdiskutiert
| Wertpapier | Beiträge | |
|---|---|---|
| 34 | ||
| 29 | ||
| 21 | ||
| 20 | ||
| 20 | ||
| 17 | ||
| 17 | ||
| 13 | ||
| 12 | ||
| 12 |
